PCSK9 inhibitors for prevention of atherosclerotic cardiovascular disease

Academic Article

Abstract

  • © 2018 National Lipid Association The discovery of proprotein convertase subtilisin kexin-type 9 (PCSK9) and the development of inhibitors of PCSK9 function appear to mark an epochal advance in clinical lipidology. PCSK9 is a circulating protein that binds to low-density lipoprotein (LDL) receptors and facilitates their lysosomal degradation following internalization in cells. Blocking PCSK9 thus increases the recycling of LDL receptors and results in more receptors on the cell surface, particularly in the liver, thereby lowering LDL levels. In this Roundtable, we discuss the recent large cardiovascular outcomes trials in which evolocumab and alirocumab, monoclonal antibodies directed against PCSK9, successfully reduced major cardiovascular events. We discuss the safety of these drugs as well as the safety of maintaining very low LDL cholesterol levels. Finally, we address pragmatic considerations affecting the use of PCSK9 inhibitors in clinical practice.
  • Authors

    Published In

    Digital Object Identifier (doi)

    Author List

  • Bittner VA; Giugliano RP; Brinton EA; Guyton JR
  • Start Page

  • 835
  • End Page

  • 843
  • Volume

  • 12
  • Issue

  • 4